Drug Patents owned by Eli Lilly And Co

1. List of Axiron drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784878 ELI LILLY AND CO Transdermal delivery rate control using amorphous pharmaceutical compositions
Jul, 2023

(5 months from now)

US8993520 ELI LILLY AND CO Method and composition for transdermal drug delivery
Jun, 2026

(3 years from now)

US9180194 ELI LILLY AND CO Method and composition for transdermal drug delivery
Jun, 2026

(3 years from now)

US8419307 ELI LILLY AND CO Spreading implement
Feb, 2027

(4 years from now)

US8807861 ELI LILLY AND CO Spreading implement
Feb, 2027

(4 years from now)

US9289586 ELI LILLY AND CO Spreading implement
Feb, 2027

(4 years from now)

US8435944 ELI LILLY AND CO Method and composition for transdermal drug delivery
Sep, 2027

(4 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 23 November, 2010

Treatment: A method of transdermally delivering testosterone; A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of increasing the testosterone blood level of a person in need thereof; A method of transdermal administration of a physiologically active agent to a subject.

Dosage: SOLUTION, METERED;TRANSDERMAL

How can I launch a generic of AXIRON before it's patent expiration?
More Information on Dosage

2. List of Baqsimi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6938798 ELI LILLY AND CO Fluid or powdery product dispensing device
Jan, 2022

(1 year, 30 days ago)

US10213487 ELI LILLY AND CO Nasal powder formulation for treatment of hypoglycemia
Feb, 2036

(13 years from now)

US10894133 ELI LILLY AND CO Device for dispensing a fluid product
Jan, 2038

(14 years from now)

US10765602 ELI LILLY AND CO Medication delivery systems and methods
Sep, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jul 24, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 24 July, 2019

Treatment: Treatment of severe hypoglycemia in patients with diabetes

Dosage: POWDER;NASAL

More Information on Dosage

3. List of Mounjaro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(8 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(8 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 13 May, 2022

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

4. List of Olumiant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8158616 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Mar, 2029

(6 years from now)

US9089574 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
Nov, 2032

(9 years from now)

US11045474 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections
Nov, 2032

(9 years from now)

US9737469 ELI LILLY AND CO Methods for treating hair loss disorders
Mar, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) May 10, 2025
New Chemical Entity Exclusivity (NCE) May 31, 2023

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of rheumatoid arthritis; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo); Treatment of adult patients with severe alopecia areata

Dosage: TABLET;ORAL

How can I launch a generic of OLUMIANT before it's patent expiration?
More Information on Dosage

5. List of Reyvow drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7423050 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Apr, 2025

(2 years from now)

US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Mar, 2023

(a month from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage

6. List of Verzenio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7855211 ELI LILLY AND CO Protein kinase inhibitors
Dec, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2022
New Patient Population (NPP) Oct 12, 2024
New Indication (I) Oct 12, 2024

Drugs and Companies using ABEMACICLIB ingredient

NCE-1 date: September, 2021

Market Authorisation Date: 28 September, 2017

Treatment: In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; In combination with fulvestrant for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy; As monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hr-positive, her2-negative, node-positive, early breast cancer at high risk of recurrence and a ki-67 score >=20%; In combination with fulvestrant for the treatment of adult patients with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endrocrine therapy; In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, and men with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in